82 results about "Neuritis" patented technology

The invention provides an extraction and detection method of a day lily active matter and application of the day lily active matter in anti-neuritis. Hemerocallis fulva contains various bioactive substances including flavone, polysaccharide and saponin, and the substances have potential application value in the fields of medicines and health care products. The invention provides a method for extracting the active components step by step, and rapid identification and detection are carried out by utilizing technologies such as fluorescence and ultraviolet-visible spectrophotometry. In addition, the invention also develops a detection method for evaluating the anti-neuritis effect of the active substances. Lipopolysaccharide (LPS) is used for stimulation to establish an inflammation model, day lily active substances are added, and the active substances are found to be capable of remarkably inhibiting generation and release of inflammatory factors and promoting growth and differentiation of neurons. Scientific basis is provided for developing new neuritis treatment methods, related drugs and the like.

The present application relates to novel substituted heterocyclic carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and / or prevention of diseases and to their use for producing medicaments for the treatment and / or prevention of diseases, in particular for the treatment and / or prevention of breathing difficulties including sleep-induced breathing difficulties such as central and obstructive sleep apnoea, snoring (primary and obstructive snoring), dysphagia, peripheral and cardiac vascular disorders including diabetic microangiopathies and disorders of the peripheral and central nervous system including neurodegenerative and neuroinflammatory disorders.

The present application relates to adrenergic receptor ADRAC2 antagonists, to novel substituted heterocyclic carboxamides, to a method for the production thereof, to the use thereof alone or in combination for the treatment and / or prophylaxis of diseases and to the use thereof for producing medicaments for the treatment and / or prophylaxis of diseases, in particular for the treatment and / or prophylaxis of dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea. Such as central and obstructive sleep apnea, snoring (primary and obstructive snoring); dysphagia; peripheral and cardiovascular conditions, including diabetic microangiopathy; and peripheral and central nervous system disorders, including neurodegenerative and neuroinflammatory disorders.

The present application relates to novel substituted heterocyclic carboxamides, to a method for the production thereof, to the use thereof alone or in combination for the treatment and / or prophylaxis of diseases and to the use thereof for producing medicaments for the treatment and / or prophylaxis of diseases, in particular for the treatment and / or prophylaxis of dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea. Such as central and obstructive sleep apnea, snoring (primary and obstructive snoring); dysphagia; peripheral and cardiovascular conditions, including diabetic microangiopathy; and peripheral and central nervous system disorders, including neurodegenerative and neuroinflammatory disorders.

The application relates to the technical field of targeted drugs, in particular to an organic compound and application of the organic compound in preparation of a PET probe for targeting 18kDa translocation protein and in pharmacy. 18 Or F. Compared with a conventional PET probe, the organic compound has the targeting TSPO characteristic, can be used for preparing the PET probe for targeting TSPO, is stable in in-vivo plasma metabolism, has lower non-specific uptake, and can be used for diagnosis, scientific research and drug preparation of neuroinflammation.

Provided is a composition for preparing a medicament for treating diabetic peripheral neuropathy. The pharmaceutical composition comprises cobra venom phospholipase A2, or a combination of cobra venom phospholipase A2 and at least one additional drug for treating diabetic peripheral neuropathy. The diabetic peripheral neuropathy is characterized by a slowdown in motor nerve conduction velocity and / or sensory nerve conduction velocity of a patient, and / or hypoesthesia or loss of sensation in both lower limbs. The pharmaceutical composition can be used to ameliorate the clinical symptoms described above in patients with diabetic peripheral neuropathy, and belongs to the field of biopharmaceuticals.

The invention belongs to the technical field of medicines, and particularly relates to a phenanthroindolizidine alkaloid compound and application thereof. The invention discloses two kinds of phenanthroindolizidine alkaloid compounds, namely (-)-(R)-13a alpha-secoxanthin and (-)-(R)-13a alpha-6-O-desmylanthin, which are derived from a traditional Chinese medicine cynanchum atratum, and discloses the obvious anti-neuritis activity of the phenanthroindolizidine alkaloid compounds for inhibiting the generation of nitric oxide. Animal experiments prove that by intraperitoneal injection of the (-)-(R)-13a alpha-secoxanthin and the (-)-13a alpha-6-O-desmylanthin, the autonomous movement ability of a depression mouse is remarkably improved, the exploration behavior of the mouse is recovered, the anxiety symptom of the mouse is relieved, and the despair behavior of the mouse is relieved. The invention provides a new lead compound for research and development of new antidepressant drugs.

The invention belongs to the technical field of biological medicines, and particularly relates to application of Chi3l1 as a target spot in preparation of a medicine for preventing or treating secondary brain injury after cerebral hemorrhage. By integrating space transcriptomics and a mononuclear RNA sequencing technology, the spatial heterogeneity and cell type specificity of gene expression in ICH afterbrain tissue are deeply analyzed, a group of astrocyte subgroups AST1 with neuritis existing around hematoma in the acute stage after cerebral hemorrhage is identified, Chi3l1 is determined as a key inflammatory effect factor of the AST1 subgroups, and the AST1 subgroups with neuritis are used as the key inflammatory effect factor of the AST1 subgroups. And the influence of the gene on the phenotypic transformation of astrocytes and microglial cells is verified. The discovery provides an important theoretical basis for developing a treatment strategy of targeting Chi3l1, and is expected to improve neuroinflammatory response and neurological dysfunction after ICH by regulating and controlling expression of the AST1 subgroup and Chi3l1, and opens up a new direction for treatment of ICH.

The present invention discloses a crotan-type diterpene compound, its preparation method, and application, relating to the field of pharmaceutical technology. The present invention extracts a crotan-type diterpene compound of novel structure from sage. The compound has significant inhibitory activity against neuronal inflammation, exhibits excellent anti-neuritis effects, and significantly inhibits inflammatory mediators. It can be developed as a therapeutic drug for neurodegenerative diseases.

The invention provides a cassane diterpenoid compound and an application of the cassane diterpenoid compound in preparation of an anti-neuroinflammation medicine. Six novel cassane diterpenoid compounds are separated from mysorethorn, and a preparation method of the six compounds is provided. According to the present invention, the inhibition effect of lipopolysaccharide (LPS)-induced BV-2 microglial cells on NO production is determined, and the six compounds have anti-neuroinflammatory activity, and particularly, the compounds 4 and 5 have good anti-inflammatory effect compared with other compounds, and have the potential of anti-neuroinflammatory drug preparation.

The invention provides a dendrobium officinale exosome composition loaded with miR-146a and miR-124 as well as a preparation method and application of the dendrobium officinale exosome composition loaded with miR-146a and miR-124. According to the present invention, the dendrobium officinale exosome has the antioxidant function, the miR-146a and the miR-124 have the synergistic anti-inflammatory function, the dendrobium officinale exosome provides the delivery carrier for the miR-146a and the miR-124, the stability and the anti-inflammatory function of the miR-146a and the miR-124 are improved, and the pharmaceutical composition EXE-miR-146a-124 for treating the neuritis and the related diseases thereof is finally developed. The invention not only provides a safe and efficient miRNA delivery system, but also endows the miRNA delivery system with neuroprotection and anti-inflammatory effects, and provides a brand new and naturally sourced intervention scheme for treatment of nervous system inflammatory diseases.

The invention provides saCNTF-DSF-LNP composite nanoparticles as well as a preparation method and application of the saCNTF-DSF-LNP composite nanoparticles, and particularly relates to application of the saCNTF-DSF-LNP to preparation of medicines for treating diseases related to optic nerve injury. The method comprises the following steps: S1, preparing self-amplification CNTF RNA, and naming the self-amplification CNTF RNA as saCNTF; s2, preparing lipid nano particles entrapped with the disulfiram DSF; s3, quickly adding the ethanol phase containing the disulfiram DSF-lipid mixture into the aqueous phase containing the saCNTF, and mixing, so that the nanoparticles are formed by self-assembly; s4, purifying the nano particles by using an ultrafiltration centrifugal device to obtain saCNTF-DSF-LNP; the invention provides a preparation method and application of saCNTF-DSF-LNP, the saCNTF-DSF-LNP can inhibit neuroinflammation driven by acute pyroptosis, and continuous neurotrophic support is provided for RGC survival and long-term axon regeneration; according to saCNTF-DSF-LNP, continuous expression of CNTF is achieved through saRNA, efficient targeted delivery is achieved by means of LNP so as to reduce off-target toxicity of DSF, and a new treatment strategy is provided for neuritis and degenerative diseases.

The invention relates to the technical field of biological medicines, and particularly discloses application of oridonin in preparation of anti-neuritis medicines. The oridonin disclosed by the invention can be used for inhibiting neuroinflammation and inhibiting programmed death of neuronal cells, so that neurons are protected. Chemical structural formula of oridonin is as follows: # imgabs0 #

The present disclosure provides single or double stranded interfering RNA molecules (e.g., siRNAs) that target a transmembrane 4 domain AGA (MS4A6A) gene. The interfering RNA molecule may contain a specific pattern of nucleoside modification and inter-nucleoside linkage modification as a pharmaceutical composition comprising the interfering RNA molecule. The siRNA molecule may be a branched siRNA molecule, such as a two-branched, three-branched or four-branched siRNA molecule. The disclosed siRNA molecules may also be characterized by a 5 '-phosphorus stabilizing moiety and / or a hydrophobic moiety. In addition, the present disclosure provides methods for delivering the siRNA molecules of the present disclosure to a subject, such as the central nervous system of a subject identified as having a neuroinflammatory disease (e.g., Alzheimer's disease).

The present disclosure provides single- or double-stranded interfering RNA molecules (e.g., siRNA) that target a SiglecS (CD33) gene. The interfering RNA molecules may contain specific patterns of nucleoside modifications and internucleoside linkage modifications, as pharmaceutical compositions including the same. The siRNA molecules may be branched siRNA molecules, such as di-branched, tri-branched, or tetra-branched siRNA molecules. The disclosed siRNA molecules may further feature a 5′ phosphorus stabilizing moiety and / or a hydrophobic moiety. Additionally, the disclosure provides methods for delivering the siRNA molecule of the disclosure to the central nervous system of a subject, such as a subject identified as having a neuroinflammatory disease (e.g., Alzheimer's disease).

The application discloses a sesquiterpene dimer and a preparation method and application thereof, and belongs to the technical field of natural compound extraction. According to the preparation method, dried sesquiterpene dimers are extracted by refluxing with 95% ethanol, and then petroleum ether and ethyl acetate are used for extraction to obtain an extract, which can be obtained by column chromatography and semi-preparative high performance liquid chromatography, so that the method is simple, time and labor are saved, and the yield is higher. The obtained sesquiterpene dimers have high anti-neuritis activity, and have important application prospects for developing new drugs for treating senile dementia.

The present invention relates to novel compounds, more particularly to a class of substituted 4-aryl-pyridine compounds, pharmaceutically active salts, prodrugs and analogues thereof. The compounds described herein are more particularly selective adenosine receptor ligands wherein said ligands may be used for the treatment or prophylaxis of disorders including cardiovascular disorders, respiratory disorders, inflammatory and neuroinflammatory disorders, among others.

The present invention relates to a DHP-I inhibitor for use in a method for the prophylactic and / or therapeutic treatment of a neuroinflammatory disease. In some embodiments, it relates to a DHP-I inhibitor for use in a method for the prophylactic treatment of neurodegeneration. The present invention also relates to a DHP-I inhibitor for use as neuroprotectant. It further pertains to related methods for the prophylactic and / or therapeutic treatment of a neuroinflammatory disease and the use of a DHP-I inhibitor in the manufacturing of a medicament for use in these methods. The present invention also provides pharmaceutical compositions and delivery systems for use in the methods of the invention, as well as to a pharmaceutical composition or drug delivery systems suitable for administration by a route bypassing the blood brain barrier (BBB) and / or the blood retinal barrier (BRB), preferably selected intrathecal, intracranial, intranasal and / or ocular administration; or suitable for trespassing the BBB and / or the BRB.

The present disclosure describes, compositions and methods comprising a recombinant, chimeric poliovirus construct for the neuroinflammatory stimulation of microglia against neurodegenerative diseases. The compositions may include a chimeric poliovirus and a therapeutic agent capable of binding to protein aggregates associated with the neurodegenerative disease. Methods of treating neurodegenerative diseases and methods of activating microglia are also provided.

The invention provides a pharmaceutical composition for treating herpes zoster as well as a preparation method and application thereof, and belongs to the technical field of medicines. Comprising the following components in parts by weight: 8-15 parts of sticky rice, 8-15 parts of mung beans, 1-3 parts of snake slough, 8-15 parts of flying centipedes, 1-3 parts of realgar and 1-5 parts of borneol. By adding the basic components including the sticky rice, the mung bean, the snake slough, the centipede, the realgar and the borneol, the traditional Chinese medicine composition can achieve the synergistic effects of resisting viruses, relieving pain, diminishing inflammation and the like, effectively relieves the symptoms of rash, pain and the like of herpes zoster, plays a role in neuroinflammation caused by viruses, is relatively mild in medicine property, and is free of toxic and side effects. The medicine is suitable for being used by herpes zoster patients with sensitive skin.

Cembranoid macrocyclic diterpene derivatives, a preparation method therefor, and a use thereof, belonging to the field of medical technology. Disclosed are cembranoid macrocyclic diterpene derivatives, a preparation method therefor, and a use thereof. In the present invention, a series of cembranoid macrocyclic diterpene derivatives are obtained by means of column chromatography and high-performance liquid chromatography separation of an extract from Croton oleifera. Said derivatives are capable of inhibiting LPS-induced NO release in BV-2 cells and have great potential for the preparation of a medicament for neuritis-related diseases.

Disclosed is a gadolinium-based compound, and an MRI contrast agent including same. The gadolinium-based compound may be a DO3A-based gadolinium compound to which 4-hydroxybenzoic acid is bound. The MRI contrast agent may include the compound. Also disclosed is a pharmaceutical composition for preventing or treating neuroinflammatory diseases, wherein the composition comprises the compound or a pharmaceutically acceptable salt thereof.

The present application relates to adrenergic receptor ADRAC2 antagonists, to novel substituted heterocyclic carboxamides, to a method for the production thereof, to the use thereof alone or in combination for the treatment and / or prophylaxis of diseases and to the use thereof for producing medicaments for the treatment and / or prophylaxis of diseases, in particular for the treatment and / or prophylaxis of dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea. Such as central and obstructive sleep apnea, snoring (primary and obstructive snoring); dysphagia; peripheral and cardiovascular conditions, including diabetic microangiopathy; and peripheral and central nervous system disorders, including neurodegenerative and neuroinflammatory disorders.

The invention discloses a clerodane diterpenoid compound as well as a preparation method and application thereof, and relates to the technical field of medicines. The clerodane diterpenoid compound with a novel structure is extracted from salvia officinalis, has obvious activity inhibition on nerve cell inflammation, has a good anti-neuritis effect, has an obvious inhibition effect on inflammatory mediators, and can be developed as a medicine for treating neurodegenerative diseases.

The invention belongs to the technical field of medicines, and discloses a C32 cycloartane triterpenoid compound containing 3-ketone carbonyl as well as a preparation method and application of the C32 cycloartane triterpenoid compound. The method comprises the following steps: enriching triterpenoids by utilizing various separation technologies and means, taking pond fir fallen leaves as a separation target and utilizing a molecular sieve principle of gel, then sequentially carrying out silica gel column chromatography and ODS column chromatography separation to obtain a target component, and further purifying to obtain the C32 cycloartane triterpenoids with 3-ketocarbonyl groups. An in-vitro anti-neuritis experiment proves that the C32 cycloartane type triterpenoid with the 3-site keto-carbonyl group has remarkable anti-neuritis activity, can be used as an active ingredient of an anti-neuritis medicine, and has wide application.

The present invention relates to the field of biomedicine, and particularly to a kit for diagnosing neuromyelitis optica spectrum disorder (NMOSD)-associated optic neuritis using circRNA as a molecular marker and its application. Experiments have found that, compared with the control group, the expression of hsa_circRNA_054220 is downregulated in the cerebrospinal fluid of patients with NMOSD-associated optic neuritis. This indicates that hsa_circRNA_054220 is a circRNA with low expression in NMOSD-associated optic neuritis and is a biomarker that helps in the diagnosis of NMOSD-associated optic neuritis. The present invention provides a strong molecular biological basis for the diagnosis of NMOSD-associated optic neuritis, with profound clinical significance and wide applicability.

The present invention provides novel hydroquinone derivatives of formula (I), processes of preparation, as well as pharmaceutical compositions and methods of treating and / or preventing e.g. autoimmune, immunological, rheumatology, vascular disorders, ophthalmologic disorders, fibrotic disorders, metabolic and gastrointestinal disorders, neuroinflammatory and neurodegenerative diseases, neoplasms and cancer associated disorders, hormone related diseases and immunological disorders resulting from viral and bacterial infectious diseases and complications thereof. wherein R 1 is COOR 4, (CH 2 ) n COOR 4, SO 3 H, (CH 2 ) n SO 3 H or CONH-R 10; one of R 2 and R 3 is H and the other is R 5.